BridgeBio Pharma (BBIO) EBT: 2019-2025
Historic EBT for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$186.5 million.
- BridgeBio Pharma's EBT fell 13.53% to -$186.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$763.5 million, marking a year-over-year decrease of 85.50%. This contributed to the annual value of -$542.2 million for FY2024, which is 17.00% up from last year.
- BridgeBio Pharma's EBT amounted to -$186.5 million in Q3 2025, which was down 9.95% from -$169.6 million recorded in Q2 2025.
- BridgeBio Pharma's 5-year EBT high stood at -$19.1 million for Q1 2024, and its period low was -$266.2 million during Q4 2024.
- Over the past 3 years, BridgeBio Pharma's median EBT value was -$164.3 million (recorded in 2024), while the average stood at -$150.3 million.
- As far as peak fluctuations go, BridgeBio Pharma's EBT surged by 86.59% in 2024, and later tumbled by 640.71% in 2025.
- BridgeBio Pharma's EBT (Quarterly) stood at -$180.6 million in 2021, then grew by 19.62% to -$145.1 million in 2022, then tumbled by 32.37% to -$192.1 million in 2023, then slumped by 38.59% to -$266.2 million in 2024, then declined by 13.53% to -$186.5 million in 2025.
- Its last three reported values are -$186.5 million in Q3 2025, -$169.6 million for Q2 2025, and -$141.1 million during Q1 2025.